Elsevier

Gynecologic Oncology

Volume 126, Issue 2, August 2012, Pages 211-216
Gynecologic Oncology

Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule

https://doi.org/10.1016/j.ygyno.2012.04.036Get rights and content

Abstract

Objective

A multicenter phase II trial was conducted to assess the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with high-dose-rate intracavitary brachytherapy (HDR-ICBT) using a low cumulative prescribed dose schedule in patients with locally advanced uterine cervical cancer.

Methods

The Japanese Gynecologic Oncology Group (JGOG) study JGOG1066 enrolled patients with FIGO stages III–IVA uterine cervical cancer who had no para-aortic lymphadenopathy (> 10 mm) assessed by CT. Patients received definitive radiotherapy (RT) consisting of external beam whole pelvic RT and HDR-ICBT. The cumulative linear quadratic equivalent dose (EQD2) was 62–65 Gy prescribed at point A. Cisplatin 40 mg/m2 weekly was administered concurrently with RT for 5 courses.

Results

Of the 72 patients registered, 71 were eligible. With a median follow-up of 28 months, the 2-year progression-free survival rate and pelvic disease progression-free rate were 66% (95% CI, 54% to 76%) and 73% (95% CI, 61% to 82%), respectively. Progression-free survival decreased significantly with increased central tumor size (P = 0.036). The 2-year cumulative late complication rates were 24% for all grades, 9% for grade 1, 12% for grade 2, 3% for grade 3, and 0 for grades 4/5.

Conclusions

The JGOG1066 demonstrated that CCRT using HDR-ICBT with a low cumulative RT dose schedule achieved comparable outcome as those achieved with global dose schedules (EQD2 = 85 Gy) with a lower incidence of late toxicity for locally advanced uterine cervical cancer in a Japanese population.

Highlights

► The radiotherapy dose for cervical cancer differs between the US and Japan. ► This is a prospective study of chemoradiotherapy using the dose prescribed in Japan. ► Pelvic disease control and survival rates are similar to those demonstrated in the US trials.

Introduction

Concurrent chemoradiotherapy (CCRT) has been shown to be superior to definitive radiotherapy (RT) alone in several randomized controlled trials (RCTs), and is now the standard of care for loco-regionally advanced uterine cervical cancer [1]. Standard definitive RT consists of whole pelvic external beam RT (EBRT) and either high or low dose rate intracavitary brachytherapy (ICBT). The previously mentioned RCTs utilized only low dose-rate ICBT (LDR-ICBT) [1]. High dose-rate ICBT (HDR-ICBT) has become widely used in Japan [2], and many centers worldwide are also shifting to HDR-ICBT [3].

Several RCTs have demonstrated clinical equivalence in terms of both local control and toxicity between HDR-ICBT and LDR-ICBT in the setting of definitive RT (without chemotherapy) [4]. In CCRT, many investigators also reported favorable treatment results using HDR-ICBT in single institutional retrospective series [5], [6], [7], [8], [9], [10], [11], [12], [13]. The Gynecologic Oncology Group (GOG) and the Radiation Therapy Oncology Group (RTOG) now allow the use of HDR-ICBT as well as LDR-ICBT in recent clinical trials of CCRT for cervical cancer [14], [15], [16], [17], [18]. In these trials, however, the patients treated with HDR-ICBT were not evaluated separately. It is unclear whether concurrent chemotherapy delivery with RT increases late complications [19]. In view of potential narrow therapeutic window of HDR-ICBT, the optimum RT dose should be carefully determined especially in the CCRT setting. Late RT complications, even when mild to moderate (i.e., Grades 1–2), significantly reduce quality of life [20]. Recently, image-guided brachytherapy (IGBT) using CT/MRI has been investigated in order to decrease late toxicity as well as improve local control [21].

Japanese centers use lower cumulative dose schedules than those of the US and Europe [2], [3]. Favorable local control results have been obtained with these lower dose schedules in retrospective series of RT alone [22], [23]. However, these lower dose schedules have not been accepted in the US and Europe given the lack of prospective data. In this situation, prospective clinical trials on the efficacy and safety of the CCRT using HDR-ICBT with the low cumulative dose schedules are encouraged.

Based on this background, we conducted a phase II multi-institutional clinical trial on CCRT for locally advanced cervical cancer patients. Herein, we report the data of outcomes and late toxicity observed in the trial.

Section snippets

Study design

The JGOG1066 trial was a multicenter phase II prospective study aimed at evaluating the efficacy and late toxicity of CCRT using HDR-ICBT for locally advanced uterine cervical cancer patients. This study was designed by the JGOG Cervical Cancer Committee in collaboration with the Japanese radiation oncologists with expertise in the cervical cancer treatment. The study was approved by the JGOG Clinical Trial Review Committee, and the local institutional review boards (IRB) of the participating

Patient characteristics

Seventy-two patients were enrolled from 25 institutions between March 2008 and January 2009. One patient was ineligible because she had para-aortic lymphadenopathy of 10 mm in the shortest diameter assessed on pretreatment abdominal CT. She never received treatment on protocol and was not included into the following analyses. Therefore, 71 patients formed the patient cohort for this report. The clinical characteristics of the 71 patients are listed in Table 2.

Feasibility

Sixty-three of the 71 patients (89%)

Discussion

This prospective multi-institutional phase II study (JGOG1066) demonstrated that CCRT using HDR-ICBT with a low cumulative dose schedule (EQD2 = 62–65 Gy prescribed at point A) achieved a 2-year PFS rate of 66% with a low incidence (4%) of severe late toxicity in stage III and IVA uterine cervical cancer patients. The lower limit of the 95% CI for PFS was 54%, which was higher than the threshold of 40%, confirming the superiority of CCRT over historical outcomes of RT alone, although the

Conflict of interest statement

No conflict of interest.

Acknowledgments

This study was supported in part by grants from the Ministry of Health, Labor and Welfare (Grants-in-Aid for Cancer Research nos. 16-12, 20S-5 and 23-A-21), and a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Nos. 18591387 and 21591614). We thank all staff of the Kitasato University Research Center for Clinical Pharmacology, especially Ms. Miki Fukutani, for their assistance in data management.

The following Japanese Gynecologic Oncology Group

References (32)

Cited by (100)

  • Why not de-intensification for uterine cervical cancer?

    2021, Gynecologic Oncology
    Citation Excerpt :

    In contrast, the Japanese guideline has been adapted much less total dose [8]. It is evident that the latter group's local control rate is less than the higher dosage group [9,10]. Nevertheless, it cannot be ignored that the lower dosage can cure the majority of patients, which means that does de-escalation can safely be achieved in the majority of patients.

View all citing articles on Scopus

Presented in part at the 2012 Annual Meeting on Women's Cancer, Austin, Texas, March 24–27, 2012, and World Congress of Brachytherapy, Barcelona, Spain, 10–12 May, 2012.

View full text